CAR-T Cells and Anticancer Peptides: Next-Generation Therapies for Liver Cancer | Research

The takeaway

CAR-T cell therapy and anticancer peptides represent next-generation hepatocellular carcinoma treatments, with peptides offering advantages of tumor selectivity, low immunogenicity, and ease of modification.

Two new weapons for liver cancer
CAR-T cells and anticancer peptides each attack liver cancer through unique mechanisms, with peptides offering particular advantages in selectivity and engineering

What the researchers found

CAR-T cells and anticancer peptides as HCC therapies: peptides offer tumor selectivity, low immunogenicity, and engineering versatility; both approaches in clinical development.

Why it matters

HCC is the 3rd leading cause of cancer death globally. New therapeutic approaches are urgently needed.

How the study worked

Review of CAR-T cell and anticancer peptide therapeutic approaches for hepatocellular carcinoma.

What this study cannot tell us

Both approaches are still in clinical development for HCC. Liver tumor microenvironment is challenging for both.

How to read the evidence

Review of clinical development landscape.

When this study was published

Published in 2025.

The bigger picture

The convergence of cell therapy and peptide therapy for liver cancer represents the cutting edge of oncology — multiple novel approaches attacking the same target.

Questions still open

Could CAR-T cells be combined with anticancer peptides for HCC?
Which anticancer peptides are most advanced for liver cancer?
Would peptide-drug conjugates enhance HCC targeting?

Common questions

Are there new treatments coming for liver cancer?

Yes. CAR-T cells (engineered immune cells) and anticancer peptides (small tumor-killing proteins) are both in development. They work through completely different mechanisms than current treatments.

What advantage do peptides have over CAR-T?

Peptides are smaller, easier to manufacture, less immunogenic, and can be readily modified. They may be more accessible and affordable than cell-based therapies.

Read the original research

Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy.

International journal of biological macromolecules, 344(Pt 1), 150512

View on PubMed ↗Publisher’s paper ↗

Citation

Kannan, H Thamarai; Pan, Ieshita. (2026). Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy.. International journal of biological macromolecules, 344(Pt 1), 150512. https://doi.org/10.1016/j.ijbiomac.2026.150512